Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Will Biomarkers Determine What Is Next in Multiple Sclerosis?: Biomarkers in Multiple Sclerosis.
Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen.
Retinal Damage and Vision Loss in African-American Multiple Sclerosis Patients.
IFN-β Therapy Regulates TLR7-Mediated Response in Plasmacytoid Dendritic Cells of Multiple Sclerosis Patients Influencing an Anti-Inflammatory Status.
Cerebrospinal Venous Outflow in Multiple Sclerosis Patients versus Fatigue and/or Depression.
Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis.
DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime?
Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
Passive Experimental Autoimmune Encephalomyelitis in C57BL/6 with MOG: Evidence of Involvement of B Cells.
Removal of access to alemtuzumab for patients with aggressive multiple sclerosis.
Lentivirus-mediated estrogen receptor α overexpression in the central nervous system ameliorates experimental autoimmune encephalomyelitis in mice.
JNK inhibitors as anti-inflammatory and neuroprotective agents.
Inhibition of Gli1 mobilizes endogenous neural stem cells for remyelination.
Isolated cognitive relapses in multiple sclerosis.
SOX17 is expressed in regenerating oligodendrocytes in experimental models of demyelination and in multiple sclerosis.
CD226 ligation protects against EAE by promoting IL-10 expression via regulation of CD4+ T cell differentiation.
In vivo quantitative whole-brain T1 rho MRI of multiple sclerosis.
Pathological Involvement of Astrocyte-Derived Lipocalin-2 in the Demyelinating Optic Neuritis.
Barriers and Facilitators Related to Rehabilitation Stays in Multiple Sclerosis: A Qualitative Study.
Clinical manifestations of neuromyelitis optica in male and female patients.
Efficacy of A Telephone-Delivered Self-Management Intervention For Persons With Multiple Sclerosis: a Randomized Controlled Trial With a One-Year Follow-Up.
Blockade of CD127 Exerts a Dichotomous Clinical Effect in Marmoset Experimental Autoimmune Encephalomyelitis.
Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.
Effects of albendazole combined with TSII-A (a Chinese herb compound) on optic neuritis caused by Angiostrongylus cantonensis in BALB/c mice.
Developing connections amongst key cytokines and dysregulated germinal centers in autoimmunity.
Pages
« first
‹ previous
…
398
399
400
401
402
403
404
405
406
…
next ›
last »